How to make safe, efficient, and robust products By Paulius Juskevicius, Littelfuse, Inc. Consumers enjoy the benefits of ...

Natural-resource equities & other real-asset exposures outperforming QQQ this year as under-the-radar beneficiaries of AI ...

Osaka, Japan – Researchers have clarified the mechanisms by which energy loss is locally maximized at a certain rotational speed in gas-liquid two-phase flows driven by rotors, providing fundamental ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

About 3,600 Met-Ed customers in Reading and West Reading lost power Monday morning due to a Met-Ed equipment failure. The problem was discovered shortly before 9 a.m. Power restored by noon. Around ...

With a modular design that supports up to 100kW of DC fast charging output, this new collaborative charging platform gives businesses, municipalities, and fleet operators a scalable solution to ...

Quarterback Jared Goff turned in his worst performance of the season during the 16-9 loss in Week 11 against the Philadelphia Eagles. Goff struggled in part because the Detroit Lions offensive line ...

A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight loss up to 20% over 48 weeks in adults with obesity or overweight without ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) released data from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in ...

Based on these trial results, Lilly will begin enrolling Phase 3 clinical studies for the treatment of obesity next month "Obesity is a complex condition, and no single treatment works for everyone.

Eli Lilly and Co.’s amylin receptor agonist, eloralintide, showed impressive weight loss and improved tolerability in phase II results reported at ObesityWeek 2025, setting the stage for a phase III ...